Payment overview · 2025
General Payments
$394.16
18 reported records · 11 companies
Healthcare provider profile · identity verified
David Lee Christopherson, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHARLOTTE, NC · NPI 1184611485
Verified facts
What the public records show
CMS Open Payments records show David Lee Christopherson, MD received $394.16 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.72 | 23.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.13 | 20.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.85 | 14.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.85 | 7.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.87 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.80 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.24 | 4.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.11 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.05 | 4.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.01 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.53 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $394.16 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $91.72 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.25 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.85 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.85 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.81 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 195 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 664 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 499 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 133 |
| Ezetimibe | Ezetimibe | 342 | 94 |
| Simvastatin | Simvastatin | 332 | 82 |
| Omeprazole | Omeprazole | 323 | 87 |
| Lisinopril | Lisinopril | 305 | 75 |
| Losartan Potassium | Losartan Potassium | 301 | 81 |
| Fenofibrate | Fenofibrate | 299 | 72 |
| Metformin Hcl | Metformin Hcl | 247 | 72 |
| Furosemide | Furosemide | 206 | 64 |
| Methylprednisolone | Methylprednisolone | 197 | 143 |
| Eliquis | Apixaban | 195 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 48 |
| Metformin Hcl Er | Metformin Hcl | 187 | 54 |
| Alendronate Sodium | Alendronate Sodium | 174 | 48 |
| Azithromycin | Azithromycin | 170 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 39 |
| Carvedilol | Carvedilol | 132 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 44 |
| Trazodone Hcl | Trazodone Hcl | 128 | 38 |
| Potassium Chloride | Potassium Chloride | 122 | 37 |
| Gabapentin | Gabapentin | 119 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 35 |
| Allopurinol | Allopurinol | 109 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 32 |
| Farxiga | Dapagliflozin Propanediol | 104 | 25 |
| Lorazepam | Lorazepam | 99 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 98 | 31 |
| Ozempic | Semaglutide | 97 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 26 |
| Mounjaro | Tirzepatide | 82 | 19 |
| Meloxicam | Meloxicam | 79 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 75 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 16 |
| Vascepa | Icosapent Ethyl | 73 | 25 |
| Finasteride | Finasteride | 70 | 16 |
| Xarelto | Rivaroxaban | 70 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 55 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 24 |
| Jardiance | Empagliflozin | 62 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 16 |
| Sertraline Hcl | Sertraline Hcl | 59 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 47 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 51 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 33 |
| Montelukast Sodium | Montelukast Sodium | 50 | 17 |
| Famotidine | Famotidine | 48 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Tramadol Hcl | Tramadol Hcl | 46 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Celecoxib | Celecoxib | 42 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 12 |
| Atenolol | Atenolol | 41 | 12 |
| Fluconazole | Fluconazole | 41 | 25 |
| Ramipril | Ramipril | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 13 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 14 |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 32 | 16 |
| Spironolactone | Spironolactone | 32 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 23 |
| Klor-Con M20 | Potassium Chloride | 29 | 12 |
| Testosterone | Testosterone | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Valsartan | Valsartan | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Linzess | Linaclotide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $394.16 · 18 records | PFIZER INC. | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, ELIQUIS, EVENITY, LEQVIO, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, SHINGRIX, UBRELVY, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error